[Corrigendum] Receptor for activated C kinase 1 (RACK1) promotes the progression of OSCC via the AKT/mTOR pathway.

Abstract

Subsequently to the publication of the above article, an interested reader drew to the authors' attention that Fig. 3 (showing how RACK1 silencing alters the protein expression levels of tumor malignant progress markers in OSCC in vivo) contained an overlapping data panel, such that the data were derived from the same original source where they were intending to depict the results from experiments performed under different experimental conditions and Fig. 4 (showing how RACK1 expression is positively correlated with p‑AKT in OSCC tissues and cells) contained a clearly duplicated pair of data panels. The authors were able to re‑examine their original data, and have identified the data that were intended to have been shown for these figure parts. The corrected versions of Figs. 3 and 4 are shown on the next two pages, featuring the correct data for the E‑cadherin experiments in Fig. 3B and the correct enlargement panel for the RACK1 / Moderate dysplasia experiment in Fig. 4A. The authors confirm that these inadvertent errors did not have any major impact on the conclusions reported in their paper, are grateful to the Editor of International Journal of Oncology for allowing them this opportunity to publish a Corrigendum, and apologize to the readership for any inconvenience caused. [the original article was published in International Journal of Oncology 49: 539‑548, 2016; DOI: 10.3892/ijo.2016.3562].

• Authors: Xuefeng Zhang, Na Liu, Danhua Ma, Ling Liu, Lu Jiang, Yu Zhou, Xin Zeng, Jing Li, Qianming Chen
• Journal: International journal of oncology (Int J Oncol) Vol. 60 Issue 2 (Feb 2022) ISSN: 1791-2423 [Electronic] Greece
• PMID: 34981815 (Publication Type: Published Erratum)